Big Pharma Dealmakers Joined by Spunky Group of Biotech Buyers in Q4

While Novartis secured the biggest deal of the fourth quarter, a handful of riveting tales emerged from the bottom of the M&A list, including a zombie buyout and a bidding war. And no, we’re not talking about Metsera.